文献速递肾移植

高致敏肾移植患者中抗T淋巴细胞免疫球蛋白与巴利昔单抗的随机前瞻性比较研究

A Randomized Prospective Study Comparing Anti-T-Lymphocyte Igs to Basiliximab in Highly Sensitized Kidney Transplant Patients.
PubMed 文献 · Kidney Int Rep · 2020-06-02

这项法国多中心前瞻性随机预试验比较了抗T淋巴细胞免疫球蛋白(ATLG,n=32)与巴利昔单抗(n=27)在高致敏但无预存供体特异性抗体的肾移植患者中的效果。6个月和12个月治疗失败率两组无显著差异,患者生存、移植物生存、肾功能及感染率相似。结论认为两种诱导方案均可有效安全使用,但研究把握度不足需谨慎解读。

要点

  • 高致敏无预存DSA肾移植患者中,ATLG与巴利昔单抗疗效和安全性相当。
  • 6个月和12个月治疗失败率两组无统计学差异(P=0.66和P=0.62)。
  • 研究为预试验且把握度不足,结果需谨慎解读。

核心结论

  • 在高致敏无预存供体特异性抗体的肾移植患者中,ATLG和巴利昔单抗均可有效且安全地使用。
  • 由于研究把握度不足,上述结果应谨慎解读。

研究设计与样本

  • 前瞻性随机法国多中心预试验,比较ATLG(n=32)与巴利昔单抗(n=27)。
  • 纳入标准:计算群体反应性抗体≥50%,至少1个抗体平均荧光强度≥5000,且无历史预存DSA及移植当日预存DSA。

主要发现

  • 6个月治疗失败率:ATLG组18.8%(95%CI 8.9%-37.1%),巴利昔单抗组14.8%(95%CI 5.8%-34.8%),P=0.66。
  • 12个月治疗失败率:ATLG组18.8%(95%CI 8.9%-37.1%),巴利昔单抗组28.2%(95%CI 14.2%-51.2%),P=0.62。
  • ATLG组发生1例T细胞介导排斥(3.1%),巴利昔单抗组发生1例由新生DSA导致的抗体介导排斥(3.7%)。
  • 两组患者生存、移植物生存、肾脏参数及感染率相似。

关键数值与推荐

  • 治疗失败定义为活检证实的急性排斥、患者失访、移植物丢失和死亡。
  • 纳入要求计算群体反应性抗体≥50%,至少1个抗体平均荧光强度≥5000,且无预存DSA。

临床怎么用

  • 对于高致敏但无预存DSA的肾移植患者,ATLG或巴利昔单抗均可作为诱导治疗选择。
  • 临床决策时应结合患者个体情况,并注意该预试验证据强度有限。

局限性

  • 研究为预试验,样本量小,把握度不足。
  • 结果需谨慎解读,需更大规模研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Two prospective studies that were performed before the era of highly sensitive solid-phase assays have shown a lower incidence of acute rejection in highly sensitized kidney-transplant patients given polyclonal antibodies compared with those given anti-CD25 monoclonal antibodies. METHODS: This prospective pilot randomized French multicenter study aimed to compare anti-T-lymphocyte Ig (ATLG) (n = 32) and basiliximab (n = 27) in highly sensitized kidney-transplant patients without preformed donor-specific antibodies (pDSAs) as assessed by a Luminex Single-Antigen flow bead assay. Only patients with a calculated panel reactive antibody ≥50%, with at least 1 antibody with a mean fluorescence intensity ≥5000 and without a historical pDSA and without a pDSA on the day of transplantation were included. RESULTS: Treatment failure as defined by biopsy-proven acute rejection, patient lost to follow-up, graft loss, and death was observed in 18.8% (95% confidence interval [CI], 8.9%-37.1%) and 18.8% (95% CI, 8.9%-37.1%) in patients who received ATLG and 14.8% (95% CI, 5.8%-34.8%) and 28.2% (95% CI, 14.2%-51.2%) of patients who received basiliximab, respectively at 6 (P = 0.66) and 12 (P = 0.62) months post-transplantation. One T cell-mediated rejection was observed in ATLG-treated patients (3.1%). One antibody-mediated rejection due to a de novo donor-specific antibody (DSA) occurred in basiliximab-treated patients (3.7%). Patient survival, graft survival, kidney parameters, and infection rate were similar in the 2 groups. CONCLUSION: This pilot study indicates that in highly sensitized kidney-transplant patients without pDSAs, both ATLG and basiliximab can be used efficiently and safely. However, because of the lack of power, these results should be interpreted with caution.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Kamar N, Lepage B, Couzi L, et al. A Randomized Prospective Study Comparing Anti-T-Lymphocyte Igs to Basiliximab in Highly Sensitized Kidney Transplant Patients. Kidney Int Rep. 2020. PMID: 32775820. doi:10.1016/j.ekir.2020.05.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。